Inkef — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.
BiotechDeep TechHealthtechMedical DevicesAarhus, DK
Co-investorsJeito CapitalNovo HoldingsRoche Venture Fund
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)Roet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)Jason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)
Co-investorsDroia VenturesMC Healthcare VenturesMission BiocapitalMitsui Global InvestmentSanofi VenturesSV Health Investors+6 more
VarmX is developing VMX-C001, a universal bypassing agent designed to restore blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs).
BiotechMedical Devices
Co-investorsSound BioventuresUNIIQYsios CapitalBGVBioGeneration VenturesEIC+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.